X.T.L. Biopharmaceuticals Ltd ADR Dossier - Source-backed chat

X.T.L. Biopharmaceuticals Ltd ADR

XTLBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.64

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.30Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $5.7M

Enterprise Value $5.4M

Shares Outstanding 2.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

XTL Biopharmaceuticals Ltd. is undergoing a highly speculative, high-risk pivot from a public shell status into a psychedelic biotechnology platform. Following the insolvency and court-ordered liquidation of its previous primary operating subsidiary, The Social Proxy Ltd., in early 2026, Nasdaq notified XTL that it was considered a 'public shell' and faced delisting. To remedy this, XTL entered into a definitive agreement to acquire Psyga Bio Ltd., an Israeli psychedelic and functional mushroom biotech company. While this acquisition provides a new clinical pipeline (seven approved Phase 2a trials) and a licensed GMP-ready manufacturing facility, the company faces severe near-term execution risks. These include securing shareholder approval at the June 22, 2026 Extraordinary General Meeting, closing the transaction by the June 30, 2026 Nasdaq-imposed deadline, resolving its late Form 20-F filing deficiency, and maintaining its Nasdaq listing. Given these binary regulatory and corporate hurdles, a 'Hold' recommendation is warranted until listing compliance is fully stabilized and the Psyga integration begins.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5030%

XTL fails to close the Psyga Transaction by the June 30, 2026 deadline, or the Nasdaq Hearings Panel denies its request for continued listing due to the late Form 20-F filing and equity deficiencies. The ADSs are suspended and delisted from Nasdaq, forcing the company to trade on the OTC markets. Liquidity dries up, and the company struggles to raise the capital necessary to advance any clinical assets, leading to severe shareholder dilution or corporate restructuring.

Base CaseCentral scenario

$3.0050%

The company successfully obtains shareholder approval for the Psyga Transaction on June 22, 2026, and closes the acquisition by June 30, 2026. The Nasdaq Hearings Panel grants a formal extension or confirms compliance, allowing XTL to maintain its Nasdaq Capital Market listing. The company files its delayed Form 20-F for FY2025 and begins integrating Psyga's psychedelic pipeline, initiating clinical trials within the next 12 months using the committed $1.5 million private placement funding.

Bull CaseUpside scenario

$8.0020%

The company rapidly integrates Psyga Bio's assets and initiates all seven planned Phase 2a clinical trials ahead of schedule. Positive early clinical data triggers milestone-based warrant exercises, providing substantial non-dilutive funding. The company secures a major global pharmaceutical partnership for its psilocybin and ibogaine platforms, driving significant valuation expansion and establishing XTL as a premier leader in the psychedelic medicine sector.

Scenarios reflect our research view at the research date.

Key Investment Merits

Acquisition of Psyga Bio Ltd. establishes a comprehensive psychedelic biotechnology platform with a library of over 180 unique mushroom strains.
Psyga brings a licensed, GMP-ready manufacturing facility and seven approved Phase 2a human clinical trials across mental health, neurological, and addiction indications.
Secured a commitment for a $1.5 million private placement to be consummated upon the closing of the Psyga Transaction, providing near-term operational runway.
The transaction is structured as an all-stock deal, preserving XTL's existing cash reserves at closing.

Key Investment Risks

Severe delisting risk: XTL is currently non-compliant with multiple Nasdaq requirements, including the minimum stockholders' equity rule, the minimum bid price rule, and timely periodic filing rules (late Form 20-F).
The Psyga Transaction is an interested party transaction under Israeli law because XTL director Alexander Rabinovich is also the Chairman and a shareholder of Psyga, requiring rigorous shareholder approval thresholds.
The previous primary operating subsidiary, The Social Proxy Ltd., entered court-ordered liquidation in February 2026, raising questions about historical capital allocation and the recoverability of a $1.5 million intercompany loan.
High clinical and regulatory hurdles inherent in psychedelic-based drug development.

Thesis Invalidation Triggers

Failure of shareholders to approve the Psyga Transaction at the Extraordinary General Meeting on June 22, 2026.
Receipt of a final delisting and suspension notice from the Nasdaq Hearings Panel.
Failure to file the delayed Form 20-F for the fiscal year ended December 31, 2025, within the Panel's grace period.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.